FDA OKs first generic for Gleevec leukemia pill
U.S. regulators have approved a generic version of one of the first very effective - and expensive - cancer drugs, Gleevec.
The Food and Drug Administration granted a subsidiary of Indian drugmaker Sun Pharmaceutical Industries Ltd. approval to sell generic Gleevec pills, known chemically as imatinib mesylate, in 100-milligram and 400-milligram doses for chronic myeloid leukemia.
Sun Pharmaceutical, one of the world's biggest makers of generic medicines, says it will begin selling the pills in the U.S. on Feb. 1, 2016.
Gleevec, which was developed and is sold by Swiss drugmaker Novartis AG, was approved in 2003.
According to Sun, Gleevec has about $2.5 billion in annual sales in the U.S. It currently has a U.S. list price of about $10,000 per month for the more-common 400-milligram daily dosage.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Diners shaken after vehicle crashes into outdoor dining area along Perkins Road
La. absentee ballot showing vote for President Trump found stolen, opened and...
Baton Rouge couple comes up with safe way to pass out Halloween...
CDC's COVID-guidelines impact Halloween traditions
Restoring power to La's Zeta-impacted areas may take up to 10 days
Best fantasy players for week 8 in NFL: Fantasy Focus with Reggie...
Fans' Choice Award Winner 2020: Week 4 - Jacoby Howard
Ed Orgeron talks about Brennan's potential return; full Monday press conference
Friday Night Blitz: Week 5 10-23-2020
TJ Finley to replace Myles Brennan as QB this Saturday